tumor characteristics of patients with recurrence after neoadjuvant ipi nivo in melanoma
Published 2 years ago • 165 plays • Length 2:43Download video MP4
Download video MP3
Similar videos
-
2:52
opacin-neo trial rfs and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
-
27:18
adjuvant and neoadjuvant dilemmas
-
2:01
pre-treatment ctdna linked to increased risk of early recurrence in io-treated melanoma
-
2:14
the use of neoadjuvant studies to prevent melanoma from recurring
-
2:54
combining nivolumab and ipilimumab in patients with resected stage iv melanoma
-
25:50
melanoma | 2022 oneoncology conference
-
24:47
adjuvant and neoadjuvant therapy for melanoma weber 2021
-
3:35
keynote-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
-
1:20
neopele: neoadjuvant pembrolizumab and lenvatinib in resectable stage iii melanoma
-
2:04
benefits and risks of reinduction ipilimumab/nivolumab in patients with melanoma
-
0:37
tils prolong pfs compared with pembrolizumab in advanced melanoma
-
1:14
adjuvant and neoadjuvant clinical trials for melanoma
-
0:37
what is the best sequence of treatment for metastatic melanoma?
-
1:13
clinical trials investigating the treatment of melanoma
-
5:18
neoadjuvant ipilimumab and nivolumab immunotherapy for resectable stage iii melanoma
-
5:16
tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma
-
5:01
melanoma highlights from esmo 2021
-
3:15
optimal neoadjuvant io in resectable stage iii melanoma: interferon gamma signature analysis
-
9:50
role of neoadjuvant therapy for melanoma